UNIVERSITY OF ILLINOIS

Early Combination of Statins and Ezetimibe Could Prevent Thousands of Heart Attacks, Study Finds

2 months ago

• Researchers from Imperial College London and Lund University found that early combination therapy with statins and ezetimibe significantly reduces the risk of subsequent heart attacks and death in cardiac patients. • The study analyzed data from 36,000 heart attack patients, revealing that those receiving combination treatment within 12 weeks had better outcomes than patients receiving delayed treatment or statins alone. • Implementation of early combination therapy could prevent an estimated 133 heart attacks per 10,000 patients over three years, potentially saving 5,000 heart attacks in the UK over a decade.

OS Therapies Advances OST-HER2 Towards FDA Submission with Manufacturing Agreements

5 months ago

• OS Therapies has initiated commercial manufacturing for OST-HER2, an immunotherapy targeting HER2, in preparation for a BLA submission to the FDA. • The company completed a Phase 2b trial of OST-HER2 for recurrent lung metastatic osteosarcoma, with positive results reported in early 2025. • OS Therapies anticipates a Type B or Type C meeting with the FDA before submitting the BLA for accelerated or conditional approval. • A patent notice of allowance from the USPTO provides market exclusivity for OST-HER2 commercial drug product into 2040.

Vabysmo Shows Superior CST Reduction Compared to Eylea HD in DME and nAMD: Meta-Analysis

7 months ago

• A matching-adjusted meta-analysis compared Vabysmo (faricimab) and Eylea HD (aflibercept 8mg) for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). • Vabysmo demonstrated a statistically significant reduction in central subfield thickness (CST) compared to Eylea HD at week 12 in both DME and nAMD. • The meta-analysis bridged the gap between trials with differing inclusion criteria, providing insights into the comparative efficacy of these therapies. • Despite limitations, Vabysmo's superior CST improvements underscore the potential of its dual VEGF and Ang-2 inhibition in treating retinal diseases.

DOD Grant Funds Research into Neuropsychiatric Symptoms of Parkinson's Disease

8 months ago

• A collaborative research team received a $3 million grant from the Department of Defense to investigate the neuropsychiatric symptoms of Parkinson's disease. • The research aims to understand how changes in serotonin-producing neurons contribute to cognitive, sleep, and psychiatric issues in Parkinson's patients. • Researchers are exploring how L-DOPA, a common Parkinson's treatment, affects serotonin neurons and leads to uncontrolled dopamine release and side effects. • The team has identified potential medications for repurposing to treat serotonin dysfunction in Parkinson's, with access to a large patient population for clinical trials.

CIH Therapies Show Promise for Chronic Musculoskeletal Pain in Military Population

8 months ago

• A recent study investigated the effectiveness of Complementary and Integrative Health (CIH) therapies versus Standard Rehabilitative Care (SRC) for chronic pain in active-duty service members. • The SMART design trial randomized participants to CIH or SRC, with options to switch or combine treatments based on initial response, lasting for six weeks. • Both groups showed significant pain improvement over six months, with CIH demonstrating earlier benefits, suggesting it as a viable initial approach for chronic pain management. • The findings support expanding access to CIH therapies, offering clinicians confidence in recommending them as a starting point based on patient preference.

Long-term efficacy and safety of iptacopan in PNH with anaemia

a year ago

The article discusses the long-term efficacy and safety of iptacopan, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with anaemia, as presented by Prof. Antonio Risitano from the University of Naples, Italy.

Therapeutic Trials for Long COVID-19: A Call to Action

2 years ago

The article discusses the ongoing challenges and research efforts in understanding and treating Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC). It highlights the need for therapeutic trials to address the persistent symptoms affecting a significant number of individuals post-acute SARS-CoV-2 infection. The National Institutes of Health's RECOVER initiative is mentioned as a key effort in this area, focusing on understanding the biological mechanisms behind Long COVID and exploring potential treatments.